Indaptus Therapeutics Files for Sale of 1.94M Common Stock Shares
Indaptus Therapeutics has recently shared some exciting news, as they announced a $2.135 million funding round. This injection of funds is set to support the company’s ongoing research and development efforts. It’s important to note that the company will not be receiving any proceeds from this sale, as stated in a recent SEC filing.
This funding round marks a significant milestone for Indaptus Therapeutics, as they continue to make strides in the field of biotechnology. The resources provided by this funding will be instrumental in advancing the company’s mission and vision.
Indaptus Therapeutics is dedicated to pushing the boundaries of scientific innovation, and this funding round is a testament to their commitment to making a positive impact on the world. With this financial support, the company is well-positioned to continue their groundbreaking work in the realm of therapeutics.
Stay tuned for more updates on Indaptus Therapeutics as they forge ahead with their cutting-edge research and development initiatives. The future looks bright for this dynamic biotechnology company, and the possibilities are endless.
